Jeong In Gab, Kim Sung Han, Jeon Hwang Gyun, Kim Baek Hee, Moon Kyung Chul, Lee Sang Eun, Lee Eunsik
Department of Urology, Seoul National University Hospital, Seoul 110-744, South Korea.
Hum Pathol. 2009 May;40(5):668-77. doi: 10.1016/j.humpath.2008.10.010. Epub 2009 Jan 20.
We investigated the expression of apoptosis-related markers and their association with the clinical outcomes of patients with urothelial carcinoma of the upper urinary tract. A total of 112 patients with urothelial carcinoma of the upper urinary tract that had surgery from March 1998 to July 2005 were included in the study. Tissue microarray slides were used for immunohistochemistry, and immunohistochemical staining was performed to investigate the association of apoptosis-related markers with clinical outcome. Apoptosis was confirmed by the TdT-mediated DUTP nick-end labeling method to obtain the apoptotic index. Survival analysis was performed according to the Kaplan-Meier method, and the Cox proportional hazard regression model was used to compare the relative influence of different prognostic factors. Among the 112 patients, 32 (28.6%) had altered expression of p53, 30 (26.8%) of bcl-2, 62 (55.4%) of bax, 27 (24.1%) of caspase-3, and 23 (20.5%) of survivin. The expression of p53 and caspase-3 was associated with the pathologic grade (P = .035 and P = .004, respectively). Altered expression of caspase-3 was associated with the pathologic stage (P = .016). The multivariate analysis showed that the expression of survivin (hazard ratio 2.91, 95% confidence interval 1.07-7.90, P = .036) and the apoptotic index (AI) (3.35, 1.06-10.56, P = .039), as well as the T and N stages (P = .043 and P = .010, respectively) were significantly associated with the disease-specific survival. Our results suggest that survivin expression and a high apoptotic index were poor prognostic factors for survival in patients with urothelial carcinoma of the upper urinary tract. These results may help to identify a subset of patients who require adjuvant therapy or closer follow-up.
我们研究了凋亡相关标志物的表达及其与上尿路尿路上皮癌患者临床结局的关联。本研究纳入了1998年3月至2005年7月期间接受手术治疗的112例上尿路尿路上皮癌患者。组织微阵列玻片用于免疫组织化学,通过免疫组织化学染色研究凋亡相关标志物与临床结局的关联。采用TdT介导的dUTP缺口末端标记法确认凋亡,以获得凋亡指数。根据Kaplan-Meier法进行生存分析,并使用Cox比例风险回归模型比较不同预后因素的相对影响。在这112例患者中,32例(28.6%)p53表达改变,30例(26.8%)bcl-2表达改变,62例(55.4%)bax表达改变,27例(24.1%)caspase-3表达改变,23例(20.5%)survivin表达改变。p53和caspase-3的表达与病理分级相关(分别为P = 0.035和P = 0.004)。caspase-3表达改变与病理分期相关(P = 0.016)。多因素分析显示,survivin表达(风险比2.91,95%置信区间1.07 - 7.90,P = 0.036)、凋亡指数(AI)(3.35,1.06 - 10.56,P = 0.039)以及T和N分期(分别为P = 0.043和P = 0.010)与疾病特异性生存显著相关。我们的结果表明,survivin表达和高凋亡指数是上尿路尿路上皮癌患者生存的不良预后因素。这些结果可能有助于识别需要辅助治疗或更密切随访的患者亚组。